Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.65 |
| ▸ | RICTOR | Q6R327 | 3/20 | 0.65 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.65 |
| ▸ | MAPKAP1 | Q9BPZ7 | 3/20 | 0.65 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.65 |
| ▸ | PRKDC | P78527 | 2/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | FECH | P22830 | 1/20 | 0.57 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.57 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.57 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.57 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942027 | 0.93 | MTOR (0.75) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL6943110 | 0.92 | MTOR (0.69) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL6942702 | 0.88 | PIK3CA (0.83) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL6942013 | 0.88 | PIK3CA (0.83) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL13527103 | 0.88 | PIK3CA (0.70) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL12328132 | 0.87 | PIK3CA (0.58) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL6955093 | 0.87 | IGF1R (0.73) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL10189576 | 0.86 | MTOR (0.79) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL6944120 | 0.86 | MTOR (0.79) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL6944724 | 0.86 | PIK3CA (0.64) | MTORRICTORRPTORMAPKAP1MLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2385053-B1 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI PHARM INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
| US-7651687-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009008992-A2 | COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 | OSI PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | MTOR 1/4885RICTOR 2/4885RPTOR 4/4885 |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | EGFR, ERBB2, MTOR | MTOR 3/4885RICTOR 5/4885RPTOR 6/4885 |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | MTOR 1/4885RICTOR 2/4885RPTOR 4/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | MTOR 1/4885RICTOR 2/4885RPTOR 7/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | MTOR 5/4885RICTOR 3/4885RPTOR 6/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | MTOR 1/4885RICTOR 6/4885RPTOR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.